Evidence map›Paper›PMID 36439420›Full record

ArticleFrontiers in oncology2022

Total marrow irradiation reduces organ damage and enhances tissue repair with the potential to increase the targeted dose of bone marrow in both young and old mice.

Ji Eun Lim, Srideshikan Sargur Madabushi, Paresh Vishwasrao, Joo Y Song, Amr M H Abdelhamid, Hemendra Ghimire, V L Vanishree, Jatinder K Lamba, Savita Dandapani, Amandeep Salhotra and 9 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 10 institutions in 4 countries.

Ji Eun LimDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, United States.
Srideshikan Sargur MadabushiDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, United States.
Paresh VishwasraoDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, United States.
Joo Y SongDepartment of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA, United States.
Amr M H AbdelhamidDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, United States.
Hemendra GhimireDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, United States.
V L VanishreeDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, United States.
Jatinder K LambaDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gianesville, FL, United States.
Savita DandapaniDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, United States.
Amandeep SalhotraDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, United States.
Mengistu LemechaDepartment of Molecular and Cellular Biology, Beckman Research Institute, Duarte, CA, United States.
Antonio PieriniDivision of Hematology and Bone Marrow Transplantation, Perugia General Hospital, Perugia, Italy.
Daohong ZhaoDepartment of Biochemistry and Structural Biology, Univeristy of Texas (UT) Health San Antonio, San Antonio, TX, United States.
Guy StormeDepartment of Radiotherapy Universitair Ziekenhuis (UZ) Brussels, Brussels, Belgium.
Shernan HoltanBlood and Marrow Transplant Program, Department of Medicine, University of Minnesota, Minneapolis, MN, United States.
Cynthia AristeiRadiation Oncology Section, Department of Medicine and Surgery, Perugia University and General Hospital, Perugia, Italy.
Dorthe SchaueDepartment of Radiation Oncology, University of California, Los Angeles (UCLA), Los Angeles, CA, United States.
Monzr Al MalkiDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, United States.
Susanta K HuiDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, United States.
City Of Hope National Medical Center · USAzienda Ospedaliera di Perugia · ITBeckman Research InstituteCity of Hope · USThe University of Texas Health Science Center at San Antonio · USUniversitair Ziekenhuis Brussel · BEUniversity of California, Los Angeles · USUniversity of Florida · USUniversity of Minnesota · USUniversity of Perugia · IT

Funding

Conformal Total Body and Marrow Irradiation for LeukemiaR01CA154491 · NCI · UNIVERSITY OF MINNESOTA · PI HUI, SUSANTA K, WONG, JEFFREY Y · 2011 to 2024
$5.0M
NCI NIH HHS R01 CA154491
6 · The paper itself

Abstract

Total body irradiation (TBI) is a commonly used conditioning regimen for hematopoietic stem cell transplant (HCT), but dose heterogeneity and long-term organ toxicity pose significant challenges. Total marrow irradiation (TMI), an evolving radiation conditioning regimen for HCT can overcome the limitations of TBI by delivering the prescribed dose targeted to the bone marrow (BM) while sparing organs at risk. Recently, our group demonstrated that TMI up to 20 Gy in relapsed/refractory AML patients was feasible and efficacious, significantly improving 2-year overall survival compared to the standard treatment. Whether such dose escalation is feasible in elderly patients, and how the organ toxicity profile changes when switching to TMI in patients of all ages are critical questions that need to be addressed. We used our recently developed 3D image-guided preclinical TMI model and evaluated the radiation damage and its repair in key dose-limiting organs in young (~8 weeks) and old (~90 weeks) mice undergoing congenic bone marrow transplant (BMT). Engraftment was similar in both TMI and TBI-treated young and old mice. Dose escalation using TMI (12 to 16 Gy in two fractions) was well tolerated in mice of both age groups (90% survival ~12 Weeks post-BMT). In contrast, TBI at the higher dose of 16 Gy was particularly lethal in younger mice (0% survival ~2 weeks post-BMT) while old mice showed much more tolerance (75% survival ~13 weeks post-BMT) suggesting higher radio-resistance in aged organs. Histopathology confirmed worse acute and chronic organ damage in mice treated with TBI than TMI. As the damage was alleviated, the repair processes were augmented in the TMI-treated mice over TBI as measured by average villus height and a reduced ratio of relative mRNA levels of amphiregulin/epidermal growth factor (

Indexed as

agingbone marrow transplantationDNA damagetissue damagetissue repairtotal marrow irradiation

Identifiers

PMID36439420
PMCPMC9686437
OpenAlexW4308874139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.